Most biologics fail not because they lack potency, but because the immune system disagrees. Undetected immunogenic responses in the form of anti-drug antibodies (ADAs) can derail clinical trials and cost pharma billions. Today, ADA risk often becomes visible only during late-stage trials. ALP AI fixes this. We combine tonsil-derived immune organoids and generative AI to predict and prevent ADA risk in early R&D, saving years and reducing failure rates.
Founded by scientists and engineers from Caltech, ETH Zurich, Stanford, and MIT, ALP AI offers the first scalable platform for human immune response validation. With a $300B+ biologics market growing rapidly, we are building the standard for immunogenicity intelligence.